Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses.

Monica SaumoyDevika GandhiSeth BullerShae PatelYecheskel SchneiderGregory CoteMichael L KochmanNikhil R Thiruvengadam Reem Z Shariaha

Published in: Gut (2023)

Cost-effective strategies were: ESG for class I obesity and SG for class II/III obesity. Semaglutide may be cost-effective with substantial cost reduction. Given potentially higher utilisation rates with pharmacotherapy, semaglutide may provide the largest reduction in obesity-related mortality.

Keyphrases

insulin resistance
metabolic syndrome
weight loss
high fat diet induced
type diabetes
weight gain
adipose tissue
cardiovascular events
cardiovascular disease
risk factors
smoking cessation